MichaelM.FrumovitzMD

Obstetrics & Gynecology • Houston, TX

Gynecologic Oncology

Physician

Join to view full profile

Dr. Frumovitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Frumovitz's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2001 - 2005
New York Presbyterian Hospital (Cornell Campus)Residency, Obstetrics and Gynecology, 1997 - 2001
David Geffen School of Medicine at UCLAClass of 1997

Certifications & Licensure

FL State Medical License 2021 - Present
WA State Medical License 2023 - 2026
AZ State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
TN State Medical License 2023 - 2025
AL State Medical License 2023 - 2024
GA State Medical License 2023 - 2024
TX State Medical License 2001 - 2024
NY State Medical License 1999 - 2017
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology
Join now to see all

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Laparoscopic Approach to Cervical Cancer Start of enrollment: 2008 Jan 01
Completed
Not Applicable
Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix Start of enrollment: 2008 Feb 01
Terminated
Phase 2
Analysis of Parametrial Lymph Nodes as Sentinel Nodes in Patients With Cervical Cancer Start of enrollment: 2008 Feb 01
Completed
Not Applicable
Hysteroscopic Lymphatic Mapping for Endometrial Cancer Start of enrollment: 2008 Apr 01
Terminated
Phase 2
Radical Trachelectomy for Women With Early Stage Cervical Cancer Start of enrollment: 2008 Dec 16
Active, not recruiting
Cost Utility Analysis in Recurrent Ovarian Cancer Start of enrollment: 2008 Dec 01
Withdrawn
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Start of enrollment: 2011 Aug 01
Completed
Phase 3
Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Start of enrollment: 2012 Mar 01
Completed
Phase 3
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers Start of enrollment: 2018 Nov 14
Active, not recruiting
Phase 2
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix Start of enrollment: 2022 Feb 28
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study) Start of enrollment: 2022 Jan 07
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

76 citations
Overall survival after pelvic exenteration for gynecologic malignancy
Shannon N. Westin, Vijayashri Rallapalli, Bryan Fellman, Diana L. Urbauer, Navdeep Pal
Gynecologic Oncology. 2014-09-01
111 citations
Predictors of Final Histology in Patients With Endometrial Cancer
Michael Frumovitz, Diljeet K. Singh, L.A. Meyer, Daniel H. Smith, Iris Wertheim
Gynecologic Oncology. 2004-12-01
158 citations
Parametrial involvement in radical hysterectomy specimens for women with early-stage cervical cancer.
Michael Frumovitz, Charlotte C. Sun, Kathleen M. Schmeler, Michael T. Deavers, Ricardo dos Reis
Obstetrics and Gynecology. 2009-07-01

Journal Articles

Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer
Roni Nitecki, Pedro T Ramirez, Michael Frumovitz, Ana I Tergas, Alexander Melamed, JAMA Oncology
Phase II Evaluation of Nivolumab in the Treatment of Persistent or Recurrent Cervical Cancer (NCT02257528/NRG-GY002)
Alessandro D Santin, Michael Frumovitz, Natalia Buza, Samir Khleif, Elena S Ratner, Roisin E O'Cearbhaill, Michael Birrer, Gynecologic Oncology
Minimally Invasive Versus Abdominal Radical Hysterectomy for Cervical Cancer
Pedro T Ramirez, Robert L Coleman, Michael Frumovitz, The New England Journal of Medicine
Imaging and Staging of Neuroendocrine Cervical Cancer
Silvana Faria, Sanaz Javadi, Preetha Ramalingam, Michael Frumovitz, Abdominal Radiology
Join now to see all

Authored Content

Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical CancerJune 2020
Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical CancerJune 2020

Press Mentions

Researchers at Houston Methodist Find Survival Improves with Open Radical Hysterectomy in Early-Stage CancerJune 11th, 2024
Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody)December 7th, 2021
MD Anderson Launches Phase 2 HPV Vaccine StudyDecember 8th, 2018
Join now to see all